GlaxoSmithKline downgraded full-year earnings expectations, as its second-quarter profit was hit by currency moves, weak sales of its respiratory drugs and the continuing bribery investigation in China.
from WSJ.com: US Business http://ift.tt/1pcotyj
via IFTTT
from WSJ.com: US Business http://ift.tt/1pcotyj
via IFTTT
No comments:
Post a Comment